Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient ; day:16 ; month:10 ; year:2021 ; pages:1-13
Heart failure reviews ; (16.10.2021), 1-13

Creator
Severino, Paolo
D’Amato, Andrea
Prosperi, Silvia
Costi, Bettina
Angotti, Danilo
Birtolo, Lucia Ilaria
Chimenti, Cristina
Lavalle, Carlo
Maestrini, Viviana
Mancone, Massimo
Fedele, Francesco
Contributor
SpringerLink (Online service)

DOI
10.1007/s10741-021-10170-1
URN
urn:nbn:de:101:1-2021123018111618781792
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:21 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Severino, Paolo
  • D’Amato, Andrea
  • Prosperi, Silvia
  • Costi, Bettina
  • Angotti, Danilo
  • Birtolo, Lucia Ilaria
  • Chimenti, Cristina
  • Lavalle, Carlo
  • Maestrini, Viviana
  • Mancone, Massimo
  • Fedele, Francesco
  • SpringerLink (Online service)

Other Objects (12)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report

Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors

Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors

Related objects